FDW88 schreef op 24 september 2020 13:38:
[...]
Since joining as CEO in September 2019, British national Paul Hudson has increasingly shifted Sanofi’s focus towards specialty medicines for cancer and rare diseases, which he sees as ripe for innovation, abandoning the firm’s traditional focus on mass-market cardiovascular and diabetes drugs. The Principia deal was preceded by the USD 2.5 billion acquisition of immune-oncology focused biotech Synthorx Inc. in December 2019.
Sanofi has been working with Principia via a licensing deal since 2017 to develop an oral
Analysts are predicting that Sanofi’s M&A splurge will not stop with the Principia acquisition. With a reported USD 50 billion M&A war chest bolstered by relatively low debts and USD 10 billion garnered through the sale of Regeneron stock,
Hudson has stated that he is “open-minded” about doing further deals. “We have enough firepower to do multiple additional bolt-ons if that’s what we want to do,” he told the FT. “We don’t need to buy revenue but we need to amplify the value of our pipeline.”Dus focus op ''rare diseases'' - zeldzame aandoeningen (pharming) en Sanofi richt zich op expansie/overnames in geval dit waarde toevoegt, ze hebben voldoende vuurkracht.